Newsroom | 5612 results

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision, today announced that the company will present at the Eye Bank Association of America (EBAA) 2026 Annual Meeting, taking place in Indianapolis, Indiana, from June 3-6 and at the American-European Congress of Ophthalmic Surgery (AECOS) 2026 European Symposium, June 11-14 in Madrid, Spain. Aurion has been invited for the f...

NEW YORK--(BUSINESS WIRE)--Warby Parker Inc. (NYSE: WRBY) (the “Company”), a lifestyle brand focused on vision for all, today announced that the Company will be presenting at the 2026 Baird Global Consumer, Technology & Services Conference on Tuesday, June 2, 2026 at 12:50 pm Eastern Time. The presentation will be webcast live over the internet and can be accessed at https://investors.warbyparker.com/. An online archive will be available for a period of 90 days following the presentation. A...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--ViaLase, Inc., un'azienda commerciale specializzata in tecnologia medica all'avanguardia nello sviluppo di soluzioni senza incisione, basate sul laser, per il trattamento del glaucoma, oggi ha annunciato di aver concluso con successo le prime procedure FLIGHT commerciali effettuate presso il Centre for Sight di Londra dal Dott. Sheraz Daya e dal Dott. Gus Gazzard, e presso la clinica Breyer, Kaymak & Klabe Augenchirurgie di Düsseldorf, Germania, dal Dot...

ALISO VIEJO, Kalifornien, USA--(BUSINESS WIRE)--ViaLase, Inc., ein kommerziell tätiges Medizintechnikunternehmen und Pionier im Bereich schnittfreier, laserbasierter Lösungen für die Behandlung von Glaukomen, gab heute den erfolgreichen Abschluss der ersten kommerziellen FLIGHT-Eingriffe bekannt, die am Centre for Sight in London von Dr. Sheraz Daya und Dr. Gus Gazzard sowie bei Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf von Dr. Karsten Klabe durchgeführt wurden. Die ersten kommerz...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--ViaLase, Inc., een medisch technologiebedrijf in de commerciële fase dat baanbrekend werk verricht met incisieloze, lasergebaseerde oplossingen voor glaucoom, heeft vandaag de succesvolle afronding aangekondigd van de eerste commerciële FLIGHT-procedures. Deze procedures werden uitgevoerd in het Centre for Sight in Londen door dr. Sheraz Daya en dr. Gus Gazzard, en bij Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Duitsland, door dr. Karsten Klab...

ALISO VIEJO, California--(BUSINESS WIRE)--ViaLase, Inc., una empresa de tecnología médica en fase comercial pionera en soluciones láser sin incisión para tratar el glaucoma, ha anunciado hoy el éxito de los primeros procedimientos comerciales con FLIGHT. Los artífices de este logro fueron los doctores Sheraz Daya y Gus Gazzard en el Centre for Sight de Londres y el doctor Karsten Klabe en Breyer, Kaymak & Klabe Augenchirurgie, en Düsseldorf, Alemania. En estos primeros procedimientos comerc...

ALISO VIEJO, Californie--(BUSINESS WIRE)--ViaLase, Inc., une entreprise de technologie médicale en phase commerciale pionnière dans le domaine des solutions laser sans incision pour le traitement du glaucome, a annoncé aujourd’hui la réussite des premières interventions FLIGHT à visée commerciale. Celles-ci ont été réalisées au Centre for Sight à Londres par les docteurs Sheraz Daya et Gus Gazzard, ainsi qu’au cabinet Breyer, Kaymak & Klabe Augenchirurgie à Düsseldorf, en Allemagne, par le...

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today launched GoodRx Companion, a new $14.99-per-month subscription that brings together free and low-cost generic medications, affordable online care visits, and savings on additional healthcare services in one simple program. Built for a healthcare environment where consumers are increasingly shouldering more out-of-pocket costs, even when they have insurance, Companion tu...

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced management will participate in two upcoming investor conferences: 2026 Jefferies Global Healthcare Conference 1x1 Meetings: Tuesday, June 2 New York, NY Evercore 2026 Emerging Private Biotech Conference Ophthalmology Panel: Wednesday, June 24, 8:50 a.m. ET Newport, RI About Ollin Biosciences Established in 2023, Ollin Bios...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Fireside chat on Wednesday, June 3, 2026, at 5:30pm ET in New York, NY Goldman Sachs 47th Annual Global Healthcare...